This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Positive trial news pumped up shares of a few biotech companies, including Cortex Pharmaceuticals (COR - Get Report), on Tuesday while others bared their earnings.

Cortex Pharmaceuticals said Tuesday that the Food and Drug Administration gave it a green light to resume enrollment in its Alzheimer's treatment Ampakine cx717. On the basis of data submitted in April, the agency has approved a protocol with all dose levels for the study, after previously putting a hold on 600-mg and 1200-mg doses. The limitations were related to concerns over data from preclinical animal trials, according to the company. Cortex rose 64 cents, or 24%, to $3.31.

Another winner, Durect (DRRX - Get Report), announced positive results in a phase IIb clinical trial of Posidur for post-operative pain in patients undergoing inguinal hernia repair. It was the study that Durect and Nycomed are basing the advancement of Posidur into phase III trials, and the results trigger an $8 million milestone payment from Nycomed.

Durect, which gained 68 cents, or 18.2%, to $4.41, said it has scheduled an end-of-phase II meeting with the FDA in preparation for Posidur's phase III program.

Also, Nastech Pharmaceuticals (NSTK) was issued two U.S. patents for its Parathyroid Hormone Nasal Spray to treat osteoporosis and PYY nasal spray for treatment of obesity. Nastech added $1, or 8.4%, to $12.89.

Durect and Nastech Pharmaceuticals are both components of the Nasdaq Biotechnology index, which was up 0.45, or 0.05%, to 818.69.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
COR $77.40 0.44%
DRRX $1.19 -8.50%
FRX $99.00 -0.77%
JNJ $112.50 -0.34%
AAPL $91.95 -1.40%


Chart of I:DJI
DOW 17,672.15 +11.44 0.06%
S&P 500 2,049.57 -1.06 -0.05%
NASDAQ 4,708.9850 -8.1090 -0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs